Microsurgical Management of Complex Hypothalamic Hamartomas in the Era of Minimally Invasive Therapy: A Case Series and Narrative Review

Kurt R Lehner
Johns Hopkins Hospital: Johns Hopkins Medicine
https://orcid.org/0000-0001-7916-1357

Randy S. D'Amico
Lenox Hill Hospital

Ralph Rahme
Northwell Health

Julia R. Schneider
Lenox Hill Hospital

Gloria G. Privler
Lenox Hill Hospital

Lukas J. Faltings
Lenox Hill Hospital

Victor X. Du
Northwell Health

John A. Boockvar
Lenox Hill Hospital

Harold L. Rekate
Northwell Health

David J. Langer
Lenox Hill Hospital

Research Article

Keywords: Hypothalamic Hamartomas, Invasive Therapy, Narrative

Posted Date: October 20th, 2021

DOI: https://doi.org/10.21203/rs.3.rs-947196/v1

License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License

Version of Record: A version of this preprint was published at World Neurosurgery on January 1st, 2022. See the published version at https://doi.org/10.1016/j.wneu.2022.01.031.
Abstract

Introduction

Recently, there has been a paradigm shift in the management of hypothalamic hamartoma (HH) from traditional microsurgical techniques to less invasive alternatives such as stereotactic radiosurgery and laser interstitial thermal therapy. However, large and extensive HH may fail to respond to minimally invasive therapies, ultimately necessitating microsurgery.

Methods

All patients who underwent microsurgical resection of a complex HH by the 2 senior authors (D.J.L., H.L.R.) in 2011-2017 were included. Charts were retrospectively reviewed and demographic, clinical, imaging, and outcome data were recorded.

Results

8 patients, 7 children and 1 adult, with a mean age of 7 years (10 months-27 years), were included. Of those, 2 had failed previous treatments. All 7 children presented with pharmacoresistant gelastic seizures and cognitive dysfunction, 6 exhibited central precocious puberty, and 3 had behavioral problems. Other seizure types affected 6/8 patients. Mean lesion size was 21.6 mm (14-31), all with interpeduncular extension and 5 with intraventricular extension (Delalande type I: 3, type III: 4, type IV: 1). A frontotemporal orbitozygomatic (FTOZ) approach with optic nerve decompression was used in all patients, supplemented by another approach in 3 (endoscopic transventricular: 3, transcallosal: 1). Gross total resection was achieved in 6 patients and subtotal resection in 2. Transient complications occurred in 3 patients (37.5%): self-limited sodium imbalance (n=3), subdural hygroma (n=2). Permanent complications occurred in 2 patients (25%): perforator infarct (n=1), short-term memory loss (n=1). All patients experienced seizure resolution postoperatively with preserved hypothalamic-pituitary axis function. After a mean follow-up of 41 months (2-66), 7 patients remain seizure-free, while 1 has rare recurrent seizures. Cognitive and behavioral symptoms improved significantly in all patients.

Conclusion

For large HH with interpeduncular extension, microsurgery via the FTOZ approach is a safe and highly effective treatment modality.

Introduction

Hypothalamic hamartomas (HH) are benign lesions found in 1-2 per 100,000 persons. Clinically, HH presents with gelastic seizures and a catastrophic drug-resistant epilepsy with or without precocious puberty. Cognitive and behavioral disturbances including aggressive behavior and "rage attacks" are also observed in patients with HH. Treatment of HH is surgical to disconnect or remove the HH from the normal brain. Minimally invasive approaches including laser interstitial thermal therapy (LITT) and stereotactic radiosurgery (SRS) are increasingly favored in treating HH. However, microsurgical approaches are still necessary for large lesions or those resistant to minimally invasive therapy.

Frontotemporal-orbitozygomatic (FTOZ) craniotomies provide an approach to the anterior skull base with little retraction of the brain and excellent functional and cosmetic results. Here, we report our experience utilizing an FTOZ approach for resection of HH. We also provide a concise review of the literature comparing FTOZ resection of HH to other commonly used approaches to outline the role of FTOZ in management of hypothalamic hamartoma.

Methods

Patients and clinical course

A retrospective review was carried out on all patients undergoing resection of HH using an FTOZ craniotomy at our institution between January 2011 and December 2017. This included outpatient visits, operative reports, and review of MRI scans. All procedures and chart review were performed in accordance with local IRB approval.

Literature search

A PubMed literature search was conducted for relevant literature in English during the years 1990-2018. The terms "hypothalamic hamartoma", "surgery", "microsurgery", "laser interstitial thermal therapy", "LITT" "endoscopic", "radiosurgery", "radiofrequency", "gamma knife", and "craniotomy" were used in various combinations for the search. The literature was reviewed and the relevant results regarding the following aspects: 1) Craniotomy for resection of HH; 2) endoscopic resection of HH; 3) LITT ablation of HH; 4) radiosurgery for HH.
Results

Clinical characteristics

From 2011-2017 8 patients with HH underwent 9 hospital admissions for resection of HH with a FTOZ or combined approach (Table 1).

Seizure semiology was predominantly gelastic. 1 patient (patient 8) presented with CPS and generalized tonic-clonic (GTC) seizures. The duration of seizures prior to surgery at our institution ranged from 10 months to 11 years, the frequency of seizures ranged from 4-5 seizures per week to greater than 100 episodes per day.

6 patients in our series showed signs of central precocious puberty (CPP). All pediatric patients showed signs of cognitive dysfunction or developmental delay at the time of surgery. 2 patients had received a diagnosis of attention-deficit hyperactivity disorder. 3 patients showed signs of inappropriate aggression with regular tantrums or rage attacks. 2 patients in our series had undergone prior surgical procedures for resection of HH at other institutions.

Imaging findings

MRI characteristics of hypothalamic hamartomas in our series are shown in Table 2. 5 patients had sessile type hamartomas with primarily vertical attachment to the hypothalamus. 3 patients had pedunculated hamartomas with a primarily horizontal attachment. All HH were nonenhancing and isointense to gray matter on T1W imaging and were either hyperintense or isointense on T2W imaging. The lesions occupied the suprasellar (SS) and interpeduncular (IP), and prepontine (PP) cisterns, five of which had an intraventricular (IV) component. Size of the lesions in the greatest dimension ranged from 10mm to 31mm. Based on the Delalande and Fohlen classification system, 3 patients had class 1 HH’s, 4 patients had class 3 HH’s, and one patient had a class 4, or giant, HH. Of note, concern for optic nerve compression was present in every patient’s MRI.

Surgical characteristics and complications

Surgical technique for the FTOZ craniotomy and other approaches to a HH have been previously described. All patients were consented for a possible two-stage procedure in the same hospital stay beginning with an FTOZ craniotomy followed by either a TAIF or endoscopic approach (Table 3). Significantly, the optic nerve was noted to be splayed intra-operatively in all patients and optic nerve decompression was performed allowing mobilization of the nerve to enlarge the optico-carotid triangle to facilitate resection. 5 patients underwent resection of HH utilizing an OZ craniotomy alone. 3 patients were treated with a combined approach. Length of stay (LOS) ranged from 5-21 days with an average LOS in patients undergoing a single procedure of 7.2 days and 11.5 days in patients undergoing a combined procedure. An endocrinologist managed the patients’ post-operative endocrine care.

Patient 1 underwent an FTOZ craniotomy with an estimated 95% resection. His post-operative course was complicated by hyponatremia and a subdural hygroma requiring a burr hole for drainage, delaying the second stage of his procedure by two months. Following resolution of the hygroma, he underwent endoscopic transventricular resection of the residual ipsilateral to the FTOZ craniotomy resulting in a GTR. Patients 4, 5, 6, and 8 were treated with an FTOZ craniotomy ipsilateral to the HH’s most extensive attachment. The course of the remaining patients is described below.

Complications relating to the surgical procedures included hyponatremia in two patients, transient diabetes insipidus (DI) in one patient, and a triphasic response in one patient leading to seizures. One patient developed a UTI. One patient was found to have a small thalamic stroke ipsilateral to the craniotomy resulting in long-term spasticity. Two patients developed subdural hygromas with one requiring surgical drainage. One patient developed short-term memory loss following his procedure.

Outcomes

Patient follow-up ranged from 2 months to 5 years. All patients experienced a decrease in seizure frequency following the final resection of HH. 6 patients experienced a 100% decrease in seizures. In 2 patients (patient 3 and 4) who underwent subtotal resection of HH, 1 patient had initially decreased seizure frequency before gelastic seizures recurred. Patient 4 had a 100% decrease in seizures until 3 years post-op when he developed rare recurrent gelastic seizures occurring 1-2 times per week. Patient 5 experienced a 100% decrease in gelastic seizures but had new complex partial seizures (CPS) occur 4 years post-operatively with MRI and electrographic findings consistent with mesial temporal lobe sclerosis (MTLS). All patients greater than 1-year post-op are no longer taking AEDs.

3 out of 4 patients receiving hormonal therapy for CPP no longer required treatment post-operatively. 2 patients (patients 1 and 2) experienced recurrent puberty; one required long-term medical therapy. No patients required treatment for permanent DI. 3 patients experienced increased appetite with significant weight gain post-op. Parents noted improved behavior and decreased rage attacks in all patients displaying signs of aggression pre-operatively.
Patient 2

A 34-month-old boy presented with 1 year of infantile spasms, gelastic, and complex partial seizures and signs of precocious puberty. His parents reported temper tantrums. MRI revealed a 21x14x19mm hypothalamic hamartoma (Figure 1A).

Due to the involvement of the interpeduncular cistern and the third ventricle as well as the size of the lesion and proximity to the optic nerve, the decision was made for a two-stage procedure for resection of the lesion. Stage one resection was carried out via a right-sided FTOZ craniotomy due to the predominance of the lesion on the right side. Intra-operatively, the ipsilateral optic nerve was noted to be splayed, and an optic nerve sheath fenestration and optic canal decompression was completed resulting in a significant decompression and allowing for mobilization of the nerve to enlarge the optico-carotid triangle through which the hamartoma was resected. An estimated 95% resection was completed (Figure 1B). The post-op course was uneventful. Four days later, stage two resection was completed via an endoscopic TAIF approach resulting in GTR. The patient experienced transient DI in the post-operative period. At the most recent follow-up, the patient was seizure-free and on no AEDs. His parents reported improved temper tantrums and abnormally increased appetite.

Patient 3

A 13-month-old girl presented with 11 months of gelastic seizures occurring >100 times per day and language regression and concern for precocious puberty. MRI revealed a 27x31x22mm HH (Figure 2A). The patient's parents elected for surgical management.

Due to the size of the lesion with involvement of the third ventricle and the basal cisterns and proximity to the optic nerve, a two-stage approach was planned involving a skull base and transcallosal approach. The patient underwent a left-sided FTOZ craniotomy. As in patient 2, the ipsilateral optic nerve was noted to be splayed, and an optic nerve decompression was completed. 90% resection was completed leaving the intraventricular portion of the HH. 6 days later, the patient underwent a left-sided TAIF for resection of the residual resulting in 95% resection. The patient's post-operative course was complicated by transient hyponatremia and a urinary tract infection requiring antibiotics. The patient was started on an AED post-operatively. 1 month after the second stage of the operation, the patient developed recurrent severe dacrycystic seizures. She returned to the OR approximately 2 months after the second stage of her initial operation for an endoscopic transcallosal resection of the residual resulting in an estimated 99% resection and complete disconnection of the HH (Figure 2B). At 9-month follow-up, the patient was seizure free, but was experiencing hyperphagia and weight gain. She had developed a small subdural hygroma which was managed conservatively.

Patient 7

A 12-year-old boy with a history of hypothalamic hamartoma status-post endoscopic-TAIF resection as a 2-year-old resulting in an estimated 80% resection and LITT ablation as an 8-year-old at outside institutions presented with an estimated 300-500 gelastic seizures per day, most lasting less than 30 seconds. He had failed 4 AEDs, showed signs of precocious puberty controlled with hormonal therapy, displayed rage attacks, and had delayed speech acquisition and short-term memory loss. Physical exam revealed strabismus and blurry vision, the patient was otherwise intact. MRI demonstrated a 13x14x10mm hypothalamic hamartoma (Figure 3A). Based on the failure of comparatively less invasive approaches, the decision was made to proceed with resection of the lesion via an FTOZ craniotomy (Figure 3B). As above, the ipsilateral optic nerve was noted to be splayed, and an optic nerve decompression was completed. GTR was achieved. There were no peri-operative complications. At 6-month follow-up, the patient was seizure free with significant hyperphagia and weight gain and little improvement in his aggression.

Discussion

As HH are intrinsically epileptogenic, definitive treatment requires complete disconnection or removal. While surgical resection was the mainstay of HH treatment for many years, newer, less invasive treatments have been developed and are increasingly preferred to traditional microsurgical treatment. In this study, we demonstrate the utility and safety of the FTOZ approach for the treatment of large and/or complex HH.

Surgery for HH was first reported in 1967 via a subfrontal approach; a report in 1969 described the removal of the temporal pole to access the HH. In the late 1990's, reports of the use of SRS appeared in the literature, representing a transition towards these minimally invasive techniques. Currently, the use of LITT is increasingly advocated due to short post-operative periods and minimal morbidity. The literature reviewed in the following sections is outlined in Table 4.

Stereotactic radiosurgery (SRS)

The first series of patients treated with SRS was published in 2000. The same group has since conducted the only prospective trial examining the role of GKS in the treatment of HH. In this study of 48 patients, the majority of HH were small (types I, II, or III). 19 of 48 patients experienced seizure freedom and an additional 14 experienced a worthwhile reduction in seizures; all had functional improvement with no permanent neurological or endocrinologic side effects. 7 (14.5%) patients required microsurgery due to treatment failure. Similar results were seen in three separate studies.
The International Stereotactic Radiosurgery Society released practice guidelines for the use of GKS in treatment of HH in 2017 providing level 2 evidence that that GKS has a better risk-benefit ratio for small hypothalamic hamartomas compared to surgical methods. Other studies have noted that neurological, cognitive, and social outcomes are improved with GKS which does not carry the same risk of poor memory outcomes and increased appetite seen with microsurgical methods. The studies agree that the drawbacks of GKS include delayed treatment effect (3 years are necessary to ascertain treatment outcome), lack of efficacy for large HH, and the threat of damage to adjacent radiosensitive structures such as the optic chiasm.

**Radiofrequency ablation**

Radiofrequency ablation (RFA) is another minimally invasive approach to the treatment of HH which utilizes the conductive properties of an implanted depth electrode to thermally ablate tissue and disconnect the HH from normal parenchyma. Seizure freedom can frequently be achieved with the advantage of utilizing a depth electrode to record and locate the seizure-onset zone prior to RFA. Kameyama, et al, reported their experience with RFA utilizing 140 procedures in 100 patients with HH: 86% of patients treated reported freedom from gelastic seizures, 79% of patients reported freedom from other seizure types, and a total of 71% of patients reported complete seizure freedom. Post-operatively, transient neurological symptoms included short-term memory loss, hyperthermia, endocrine dysfunction, increased appetite, Horner’s syndrome, supplementary motor area syndrome and emotional facial paresis. 2 cases of permanent pituitary dysfunction occurred in patients who received bilateral RFA for disconnection of HH with bilateral attachment. In general, RFA appears to be best suited for ablation of disconnection of small, sessile HH. Treatment with RFA requires multiple trajectories and the authors warn against the use of bilateral RFA for disconnection to prevent endocrinologic complications.

**Laser Interstitial Thermal Therapy (LITT)**

LITT is a minimally invasive approach that accomplishes ablation of the seizure focus using an implanted laser catheter. Wilfong, et al, reported seizure freedom in 12 of 14 patients and no permanent neurologic or endocrinologic side effects. Another study reported similar outcomes with 6 of 7 patients reporting seizure freedom. Similarly, Xu, et al reported seizure freedom in 12/15 patients with gelastic seizures and 5/9 with nongelastic seizures undergoing LITT treatment; 39% of patients experienced a transient neurological deficit with 22% of patients suffering persistent. LITT treatment has resulted in a disabling amnestic syndrome in one patient. LITT can be utilized for complete ablation or disconnection of the HH, however, it may prove ill-suited for large HH with extended or bilateral connection to brain parenchyma, similar to RFA.

**Microsurgical resection**

Three approaches are utilized to treat HH microsurgically: endoscopic approaches, transcallosal approaches, and skull base approaches. Many advocate multi-stage operations for treatment of HH. Endoscopic transventricular resection can be utilized in the treatment of small HH with significant involvement of the third ventricle (Type II or III). Smaller case series have also demonstrated the efficacy of endoscopic disconnection of smaller hypothalamic hamartomas. The TAIF approach has also been advocated for HH with significant third-ventricular extension (Type 2). While the transcallosal approach is effective for the treatment of HH, it has been associated with long term reduction in memory function.

Pterional skull base approaches have yielded some success for treatment of hypothalamic hamartomas, however, access to the hypothalamus can be limited through this approach. Notably, Drees, et al, reported a mean resection of 64% in 10 patients treated with transcallosal or endoscopic-pterional/endoscopic-FTOZ approaches; it was noted that giant HH led to significant difficulty in obtaining a complete resection. No patients experienced seizure freedom. 4 patients experienced persistent hormonal disturbances and 4 patients experienced hyperphagia and weight gain post-operatively; 2 patients experienced permanent neurological deficits, and 1 patient died immediately post-operatively. Based on these reports, large HH with broad attachments to the hypothalamus which are not amenable to minimally invasive approaches benefit from complete resection which may be limited in a pterional craniotomy.

The use of the FTOZ approach and variations has been discussed previously. This approach is advocated for treatment of pedunculated HH with interpeduncular extension and an inferior or horizontal plane of attachment to the hypothalamus by providing a wide exposure of the region of the HH with improvement in access to the superior aspect of the tumor with minimal frontal lobe retraction. Additionally, optic nerve decompression and mobilization can be carried out via this approach to aid in resection through the optico-carotid triangle creating a significantly larger surgical window.

There is likely not a single ideal treatment for HH. The Delalande and Fohlen classification system classifies HH into four groups based on lesion morphology (pedunculated or sessile), intraventricular location, horizontal or vertical attachment to the hypothalamus, and lesion size. Smaller lesions are amenable to SRS, and large lesions, including giant HH, have been treated with RFT and LITT to with varying success. The utility of
these approaches is limited by proximity of the HH to critical structures such as the optic apparatus. HH with significant 3rd ventricular extension (Type 2 and 3) should be treated from above, preferably with an endoscopic approach which is thought to be less invasive than the TAIF approach with no known association to long-term memory disturbance. The TAIF approach is thought to be well suited for Type 2 lesions with simple attachment to the hypothalamus. Bilateral attachment to the hypothalamus, however, makes the endoscopic approach difficult from a single side, and if the lesion sits posteriorly over the mamillary bodies, great care must be taken to avoid damaging these structures lest devastating permanent memory disturbance occurs.

HH with significant extension into the basal cisterns and broad attachment to the inferior hypothalamus (Type 1, 3, 4) that are not amenable to SRS, RFA, or LITT create a favorable situation for skull base approaches. Compared to a pterional approach, the FTOZ approach provides a wide working corridor and our review of the literature and case series indicates a higher rate of gross total or near gross total resection when used alone or in combination. In treatment of complex HHs with intraventricular and interpeduncular components with unilateral or bilateral attachment to the hypothalamus, or a HH that has failed treatment with LITT, SRS, or another approach, a combination of transventricular and skull base approaches may be needed for adequate treatment of the lesion.

Conclusion

For large HH with complex attachment to the hypothalamus and proximity to other neural structures, microsurgery via the FTOZ approach is a safe and highly effective treatment modality. As surgical success requires the complete disconnection or removal of the HH, additional treatment with other approaches or modalities may be required for adequate treatment.

Declarations

Compliance with Ethical Standards: This study was approved by the IRB at Northwell Health.

Consent to participate: Informed consent was obtained from all individuals participating in this study.

Conflicts of interest: The authors have no relevant conflicts of interest to report.

Funding: The authors did not receive support from any organization for the submitted work. The authors have no relevant financial or non-financial interests to disclose.

Author contributions: Project was conceived and designed by David Langer, Harold Rekate, and Kurt Lehner. Manuscript was prepared by Kurt Lehner and data acquisition was completed by Kurt Lehner, Ralph Rahme, Julia Schneider, Lukas Faltings, and Gloria Privler. All authors reviewed the manuscript, revised it critically, and approved of publication. All authors agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Data availability: The datasets generated during and/or analysed during the current study are available from the corresponding author on reasonable request.

References


**Tables**

*Table 1: Pre-operative characteristics of patients with complex hypothalamic hamartomas defined as having significant intraventricular and interpeduncular extension or as undergoing a re-operation.*
Table 2: Pre-operative imaging characteristics of patients with complex HH. Class is Delalande and Fohlen classification. S: sessile; P: pedunculated; SS: suprasellar; IP: Interpeduncular; PP: prepontine; IV: Intraventricular; Iso: isointense to gray matter; Hyper: hyperintense to gray matter; Enh: enhancement; DS: dorsum sellae; VPS: Ventriculo-peritoneal shunt.

<table>
<thead>
<tr>
<th>Pt</th>
<th>Class</th>
<th>Type</th>
<th>Size (mm)</th>
<th>Cisterns</th>
<th>IV?</th>
<th>T1</th>
<th>T2</th>
<th>Enh</th>
<th>Other</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>3</td>
<td>S</td>
<td>23x25x24</td>
<td>SS, IP</td>
<td>Y</td>
<td>Iso</td>
<td>Hyper</td>
<td>No</td>
<td>Remodeling of DS</td>
</tr>
<tr>
<td>2</td>
<td>3</td>
<td>S</td>
<td>18x20x20</td>
<td>SS, IP</td>
<td>Y</td>
<td>Iso</td>
<td>Hyper</td>
<td>No</td>
<td>Remodeling of DS</td>
</tr>
<tr>
<td>3</td>
<td>4</td>
<td>S</td>
<td>27x31x22</td>
<td>SS, IP</td>
<td>Y</td>
<td>Iso</td>
<td>Iso</td>
<td>No</td>
<td>Remodeling of DS</td>
</tr>
<tr>
<td>4</td>
<td>3</td>
<td>S</td>
<td>13x15x14</td>
<td>SS, IP</td>
<td>Y</td>
<td>Iso</td>
<td>Hyper</td>
<td>No</td>
<td>Remodeling of DS</td>
</tr>
<tr>
<td>5</td>
<td>3</td>
<td>S</td>
<td>23x20x18</td>
<td>SS, IP</td>
<td>Y</td>
<td>Iso</td>
<td>Iso</td>
<td>No</td>
<td>Prior surgical changes, VPS, Remodeling of DS</td>
</tr>
<tr>
<td>6</td>
<td>1</td>
<td>P</td>
<td>19x16x20</td>
<td>SS, IP</td>
<td>N</td>
<td>Iso</td>
<td>Hyper</td>
<td>No</td>
<td>None</td>
</tr>
<tr>
<td>7</td>
<td>1</td>
<td>P</td>
<td>13x14x10</td>
<td>SS, IP</td>
<td>N</td>
<td>Iso</td>
<td>Hyper</td>
<td>No</td>
<td>Prior surgical changes, Remodeling of DS</td>
</tr>
<tr>
<td>8</td>
<td>1</td>
<td>P</td>
<td>22x25x16</td>
<td>IP, PP</td>
<td>N</td>
<td>Iso</td>
<td>Hyper</td>
<td>No</td>
<td>Chiari 1; Remodeling of DS</td>
</tr>
</tbody>
</table>

Table 3: Surgical characteristics and outcomes of orbitozygomatic (OZ) or combined approaches to hypothalamic hamartomas. EBL: estimated blood loss; LOS: length of stay; FU: follow-up; sz: seizure; AEDs: anti-epileptic drugs; Endo: endoscopic intraventricular; TAIC: transcallosal, anterior-interforniceal; GTR: gross total resection; min: minimal; SD: subdural; UTI: urinary tract infection; DI: diabetes insipidus; STM: short-term memory loss.*Pt 1 underwent two surgeries, R OZ and R Endo. Outcomes from each procedure are separated by a semi-colon. **100% reduction before gelastic seizure recurrence 3y post-op. ***4y post-op patient experiencing CPS and electrophysiologic and MRI findings consistent with mesial temporal lobe sclerosis.
<table>
<thead>
<tr>
<th>Pt</th>
<th>Approach</th>
<th>% Resection</th>
<th>EBL (cc)</th>
<th>LOS (days)</th>
<th>Early complications</th>
<th>FU</th>
<th>% Sz decrease</th>
<th>AEDs</th>
<th>Endocrine</th>
<th>Behavior change</th>
<th>Late complications</th>
</tr>
</thead>
<tbody>
<tr>
<td>1*</td>
<td>R FTOZ; R Endo</td>
<td>95%; GTR</td>
<td>50; min</td>
<td>7; 3</td>
<td>Hyponatremia, SD hygroma</td>
<td>4y</td>
<td>100%</td>
<td>0</td>
<td>Supprelin</td>
<td>Hyperphagia</td>
<td>None</td>
</tr>
<tr>
<td>2</td>
<td>R FTOZ, L Endo</td>
<td>95%; GTR</td>
<td>100; min</td>
<td>11</td>
<td>Transient DI</td>
<td>5y</td>
<td>100%</td>
<td>0</td>
<td>Recurring puberty (7y)</td>
<td>Hyperphagia, resolved aggression</td>
<td>None</td>
</tr>
<tr>
<td>3</td>
<td>L FTOZ, L TAIF; R endo</td>
<td>90%; 95%; 99%</td>
<td>100; 150; min</td>
<td>12; 5</td>
<td>Hyponatremia, UTI</td>
<td>9mo</td>
<td>100%</td>
<td>1</td>
<td>None</td>
<td>Hyperphagia</td>
<td>Transient dacrytic sz, SD Hygroma</td>
</tr>
<tr>
<td>4</td>
<td>R FTOZ</td>
<td>95%</td>
<td>50</td>
<td>5</td>
<td>None</td>
<td>4y</td>
<td>90%**</td>
<td>0</td>
<td>None</td>
<td>Improved aggression</td>
<td>None</td>
</tr>
<tr>
<td>5</td>
<td>R FTOZ</td>
<td>GTR</td>
<td>150</td>
<td>21</td>
<td>Triphasic, sz, R thalamic stroke</td>
<td>4y</td>
<td>100%***</td>
<td>0</td>
<td>None</td>
<td>None</td>
<td>Spasticity</td>
</tr>
<tr>
<td>6</td>
<td>L FTOZ</td>
<td>GTR</td>
<td>100</td>
<td>5</td>
<td>None</td>
<td>6mo</td>
<td>100%</td>
<td>1</td>
<td>None</td>
<td>Improved aggression</td>
<td>None</td>
</tr>
<tr>
<td>7</td>
<td>R FTOZ</td>
<td>GTR</td>
<td>50</td>
<td>7</td>
<td>None</td>
<td>6mo</td>
<td>100%</td>
<td>2</td>
<td>None</td>
<td>Hyperphagia, aggression unchanged</td>
<td>None</td>
</tr>
<tr>
<td>8</td>
<td>R FTOZ</td>
<td>GTR</td>
<td>200</td>
<td>12</td>
<td>None</td>
<td>1.5y</td>
<td>100%</td>
<td>0</td>
<td>None</td>
<td>None</td>
<td>STM</td>
</tr>
</tbody>
</table>

Table 4: A summary of relevant studies examining the treatment of hypothalamic hamartoma. *All patients in this series had a subtotal resection of the HH, hence the low incidence of seizure freedom in these patients.
<table>
<thead>
<tr>
<th>Series</th>
<th>Surgical Approach</th>
<th>Subjects</th>
<th>Seizure freedom (%)</th>
<th>Worthwhile improvement in seizures (%)</th>
<th>Permanent Neurological Complications (%)</th>
<th>Permanent endocrinologic complications (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chibbaro, et al(^7)</td>
<td>Endoscopic</td>
<td>14</td>
<td>8 (57)</td>
<td>2 (14)</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Fohlen, et al(^11)</td>
<td>Endoscopic</td>
<td>3</td>
<td>2 (67)</td>
<td>1 (33)</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Drees, et al(^9)</td>
<td>Endoscopic</td>
<td>22</td>
<td>8 (36)</td>
<td>14 (67)</td>
<td>1 (5)</td>
<td>Hyperphagia (59)</td>
</tr>
<tr>
<td>Ng, et al(^23)</td>
<td>Endoscopic</td>
<td>37</td>
<td>18 (49)</td>
<td>8 (22)</td>
<td>STM (8)</td>
<td>0</td>
</tr>
<tr>
<td>Choi, et al(^8)</td>
<td>Endoscopic</td>
<td>4</td>
<td>2 (50)</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Rosenfeld, et al(^33)</td>
<td>TAIF</td>
<td>5</td>
<td>3 (60)</td>
<td>2 (40)</td>
<td>0</td>
<td>Hyperphagia (40)</td>
</tr>
<tr>
<td>Andrew, et al(^15)</td>
<td>TAIF</td>
<td>5</td>
<td>1 (20)</td>
<td>4 (80)</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Ng, et al(^24)</td>
<td>TAIF</td>
<td>26</td>
<td>14 (54)</td>
<td>9 (41)</td>
<td>STM (8)</td>
<td>Panhypopituitarism (8)</td>
</tr>
<tr>
<td>Roth, et al(^34)</td>
<td>TAIF/Endoscopic</td>
<td>2</td>
<td>2 (100)</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Fohlen, et al(^11)</td>
<td>Pterional</td>
<td>14</td>
<td>3 (21)</td>
<td>11 (79)</td>
<td>2 (14)</td>
<td>Hyperphagia (7); panhypopituitarism (14)</td>
</tr>
<tr>
<td>Fohlen, et al(^11)</td>
<td>Endoscopic s/p pterional</td>
<td>7</td>
<td>3 (43)</td>
<td>1 (14)</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Jayalakshmi, et al(^15)</td>
<td>Pterional</td>
<td>3</td>
<td>2 (66)</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Drees, et al(^9)</td>
<td>TAIF, combined TAIF/Endoscopic, Combined pterional or FTOZ/endoscopic</td>
<td>10</td>
<td>0</td>
<td>Unknown</td>
<td>2 (29)</td>
<td>(57)</td>
</tr>
<tr>
<td>Abla, et al(^1)</td>
<td>FTOZ</td>
<td>10</td>
<td>4 (40)</td>
<td>4 (40)</td>
<td>VF cut (10); Hemiparesis (10); DI (10); Poikilothermia (10)</td>
<td></td>
</tr>
<tr>
<td>Palmini, et al(^27)</td>
<td>Pterional</td>
<td>12</td>
<td>2 (17)</td>
<td>8 (67)</td>
<td>1 (8)</td>
<td>0</td>
</tr>
<tr>
<td>Regis, et al(^30)</td>
<td>SRS</td>
<td>48</td>
<td>19 (40)</td>
<td>14 (29)</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Abla, et al(^2)</td>
<td>SRS or SRS s/p microsurgery</td>
<td>10</td>
<td>6 (60)</td>
<td>3 (30)</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Mathieu, et al(^18)</td>
<td>SRS</td>
<td>9</td>
<td>4 (44)</td>
<td>1 (11)</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Wilfong, et al(^43)</td>
<td>LITT</td>
<td>14</td>
<td>12 (86)</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Du, et al(^10)</td>
<td>LITT</td>
<td>7</td>
<td>6 (86)</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Xu, et al(^44)</td>
<td>LITT</td>
<td>18</td>
<td>12 (67)</td>
<td>3 (17)</td>
<td>STM (22)</td>
<td>Hypothyroid (11); weight gain (22)</td>
</tr>
<tr>
<td>Kameyama, et al(^16)</td>
<td>SRT</td>
<td>100</td>
<td>71 (71)</td>
<td>15 (15)</td>
<td>0</td>
<td>Panhypopituitarism (2); weight gain (7)</td>
</tr>
</tbody>
</table>

**Figures**
Figure 1

(A) Pre- and (B) Post-operative imaging for Patient 2 demonstrating a 18x20x20mm class 3 HH involving the suprasellar and interpeduncular cisterns with intraventricular extension. Following endoscopic and FTOZ approaches, GTR was achieved resulting in seizure freedom.

Figure 2
(A)Pre- and (B)Post-operative imaging for Patient 3 demonstrating a 27x31x22mm class 3 HH involving the suprasellar and interpeduncular cisterns with intraventricular extension. An estimated 99% resection was achieved following FTOZ, TAIF, and endoscopic resection resulting in seizure freedom.

Figure 3

(A)Pre- and (B)Post-operative imaging for Patient 7 demonstrating a 13x14x10mm pedunculated HH following attempted endoscopic resection and LITT ablation. The patient underwent an FTOZ approach to achieve GTR and seizure freedom.
Figure 4

(A) Pre- and (B) Post-operative imaging for Patient 8 demonstrating a 22x25x16mm pedunculated HH involving the interpeduncular and prepontine cisterns. The patient underwent an FTOZ approach to achieve GTR and seizure freedom.